VXRT — Vaxart Inc
NASDAQ · Healthcare · Biotechnology
$0.49
-$0.02 (-3.63%)
Vaxart Inc (VXRT) is a biotechnology company listed on NASDAQ. It is led by Steven Lo, based in 170 Harbor Way, South San Francisco, CA, United States, 94080, with about 105 employees. Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Latest reported VXRT revenue for 2025-09-30 was $72.4M. Net income was -$8.1M. Revenue was up 82.3% from 2025-06-30 to 2025-09-30. VXRT currently screens at market cap $73.0M.
Use this VXRT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VXRT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VXRT SEC filings page. Lician reads the product cache first so this HTML stays unique to Vaxart Inc even when a live quote feed is slow.
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
VXRT Key Statistics
Market Cap
$73.03M
Volume
117,491
Previous Close
$0.51
Day Range
$0.49 – $0.53
EPS
$0.00
Revenue
$28.70M
Net Income
-$66.95M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+288.9%
Profit Margin
-233.3%
Employees
105
VXRT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $28.70M | $7.38M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$66.95M | -$82.47M | -$107.76M | -$20.76M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$166.39M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$44.76M
Free Cash Flow
$0.00
Vaxart Inc Company Information
- President, CEO & Director
- Steven Lo
- Headquarters
- 170 Harbor Way, South San Francisco, CA, United States, 94080
- Website
- vaxart.com
- Phone
- 650 550 3500
- IPO / Founded
- 2018-02-12
- Sector
- Healthcare
- Industry
- Biotechnology